Biliary Stents Market By Product Type (Metal Biliary Stents, Plastic Biliary Stents), By Application (Malignant Biliary Obstruction, Benign Biliary Strictures, Biliary Leaks, Post-Surgical Complications), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCs)), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Biliary Stents Market was valued at USD 2.4 billion in 2024-e and will surpass USD 4.2 billion by 2030; growing at a CAGR of 9.8% during 2025 - 2030.

The biliary stents market is experiencing steady growth, driven by the increasing prevalence of biliary diseases, rising adoption of minimally invasive procedures, and advancements in stent technologies. Biliary stents play a crucial role in managing conditions such as malignant and benign biliary obstructions, biliary leaks, and post-surgical complications. The growing incidence of pancreatic and bile duct cancers, along with an aging population prone to biliary disorders, has further fueled market demand.

Technological advancements in stent materials and designs, including self-expanding and drug-eluting stents, have significantly improved clinical outcomes, reducing complications and enhancing patient recovery. Additionally, the increasing preference for endoscopic retrograde cholangiopancreatography (ERCP) procedures for biliary drainage has contributed to market expansion. With ongoing research and development (R&D) focused on improving stent durability and biocompatibility, the biliary stents market is poised for continued growth.

Metal Biliary Stents Dominate the Market Due to Their Superior Patency and Durability

Among product types, metal biliary stents hold the largest market share, primarily due to their longer patency, higher resistance to occlusion, and ability to provide better bile flow. These stents are widely preferred for managing malignant biliary obstructions, where long-term drainage is required. The self-expanding nature of metal stents allows for a more effective placement, reducing the need for frequent replacements.

Advancements in metal stent coatings, including anti-microbial and anti-tumor coatings, have further enhanced their performance by reducing biofilm formation and tumor ingrowth. Moreover, fully and partially covered metal stents provide additional benefits, such as improved removability and reduced risk of bile duct injury. As the demand for long-lasting and effective biliary drainage solutions grows, the adoption of metal biliary stents is expected to remain strong.

Malignant Biliary Obstruction Leads the Market Due to Rising Cases of Bile Duct and Pancreatic Cancer

The malignant biliary obstruction segment dominates the market, driven by the increasing prevalence of bile duct and pancreatic cancers, which often lead to obstructive jaundice. Biliary stenting is a critical palliative treatment for patients with inoperable malignancies, improving bile flow and alleviating symptoms. The rising adoption of minimally invasive techniques such as ERCP and percutaneous transhepatic biliary drainage (PTBD) has further propelled the demand for biliary stents in malignant cases.

The development of drug-eluting and biodegradable stents is expected to enhance treatment efficacy, providing prolonged patency and reducing tumor-related complications. With an aging population and increasing cancer incidence worldwide, the demand for biliary stents for malignant biliary obstruction is anticipated to grow steadily.

Hospitals Remain the Leading End-User Segment Due to High Volume of Biliary Procedures

Hospitals account for the largest share of the biliary stents market, primarily due to the high number of ERCP and PTBD procedures performed in these settings. Hospitals are well-equipped with advanced imaging technologies and endoscopic equipment, enabling efficient biliary stent placement and management. The presence of specialized gastroenterology and hepatology departments further contributes to the dominance of hospitals in this market.

The increasing adoption of ambulatory surgical centers (ASCs) for minimally invasive biliary interventions is also gaining traction, as these centers offer cost-effective and outpatient treatment options. However, for complex and high-risk cases requiring intensive post-procedure monitoring, hospitals remain the preferred healthcare setting for biliary stent placements.

North America Leads the Market Due to Advanced Healthcare Infrastructure and High Adoption of Minimally Invasive Procedures

North America holds the largest market share, driven by a well-established healthcare system, high prevalence of biliary diseases, and strong adoption of advanced endoscopic techniques. The U.S. dominates the regional market due to a high number of ERCP procedures, increasing healthcare expenditures, and the presence of leading medical device manufacturers.

The growing awareness of minimally invasive biliary interventions, coupled with favorable reimbursement policies, has further strengthened the market in North America. Additionally, continuous R&D investments in stent technology, including drug-eluting and bioresorbable stents, are expected to drive further growth in the region.

Competitive Landscape and Key Players

The biliary stents market is highly competitive, with key players focusing on product innovation, strategic collaborations, and geographic expansion. Leading companies in the market include Boston Scientific Corporation, Cook Medical, Medtronic, Olympus Corporation, CONMED Corporation, Taewoong Medical, and Becton, Dickinson and Company. These players are investing in next-generation stent designs, improved materials, and innovative coatings to enhance patient outcomes.

As the demand for minimally invasive biliary procedures continues to rise, market players are expected to focus on expanding their product portfolios and strengthening distribution networks to capture a larger market share. The development of cost-effective and high-performance stents, particularly for emerging markets, is likely to be a key growth strategy in the coming years.

List of Leading Companies:

• Boston Scientific Corporation
• Cook Medical
• Medtronic plc
• Becton, Dickinson and Company
• Olympus Corporation
• Terumo Corporation
• CONMED Corporation
• Merit Medical Systems
• Taewoong Medical Co., Ltd.
• B. Braun Melsungen AG
• EndoFlex GmbH
• Micro-Tech Endoscopy
• ENDO-FLEX GmbH
• Abbott Laboratories
• M.I. Tech Co., Ltd.

Recent Developments:

• In January 2025, Boston Scientific launched a next-generation drug-eluting biliary stent for improved long-term patency.
• In December 2024, Cook Medical expanded its biliary stent portfolio with new self-expandable metal stents.
• In November 2024, Medtronic announced a strategic partnership to develop AI-assisted biliary stent placement technology.
• In October 2024, Olympus Corporation introduced an advanced biodegradable biliary stent for reducing restenosis risk.
• In September 2024, Becton, Dickinson and Company received FDA approval for its latest plastic biliary stent design.

Report Scope: